Lei Yu, Lei Yan, Shi Xiang, Wang Jingjing
Department of Pathology, Qianjiang Central Hospital, Qianjiang, Hubei 433100, P.R. China.
Department of Respiratory Medicine, Qianjiang Central Hospital, Qianjiang, Hubei 433100, P.R. China.
Oncol Lett. 2022 Jun 24;24(2):277. doi: 10.3892/ol.2022.13397. eCollection 2022 Aug.
Non-small cell lung cancer (NSCLC) is a malignant tumor with a high morbidity and mortality rate that is a threat to human health. With the development of molecular targeted research, breakthroughs have been made on the molecular mechanism of lung cancer. The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene is one of the most important pathogenic driver genes of NSCLC discovered thus far. Four generations of targeted drugs for EML4-ALK have been developed, with patients benefiting significantly from these drugs. Therefore, EML4-ALK has become a research hotspot in NSCLC. The aim of the present study is to introduce the current research progress of EML4-ALK and its association with NSCLC.
非小细胞肺癌(NSCLC)是一种发病率和死亡率都很高的恶性肿瘤,对人类健康构成威胁。随着分子靶向研究的发展,肺癌的分子机制取得了突破。棘皮动物微管相关蛋白样4-间变性淋巴瘤激酶(EML4-ALK)融合基因是迄今为止发现的NSCLC最重要的致病性驱动基因之一。已经开发出四代针对EML4-ALK的靶向药物,患者从这些药物中受益匪浅。因此,EML4-ALK已成为NSCLC的研究热点。本研究的目的是介绍EML4-ALK的当前研究进展及其与NSCLC的关系。